tiprankstipranks
Trending News
More News >
Shanghai Haohai Biological Technology Co., Ltd. Class H (HK:6826)
:6826
Hong Kong Market
Advertisement

Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) AI Stock Analysis

Compare
0 Followers

Top Page

HK:6826

Shanghai Haohai Biological Technology Co., Ltd. Class H

(6826)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
HK$29.00
▲(5.92% Upside)
The overall stock score of 70 reflects strong financial performance and reasonable valuation, offset by bearish technical indicators. The company's robust revenue growth and profitability are significant strengths, but missing data for 2024 and bearish market momentum present challenges. The attractive dividend yield adds a positive aspect for income-focused investors.

Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) vs. iShares MSCI Hong Kong ETF (EWH)

Shanghai Haohai Biological Technology Co., Ltd. Class H Business Overview & Revenue Model

Company DescriptionShanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
How the Company Makes MoneyShanghai Haohai Biological Technology Co., Ltd. generates revenue primarily through the sale of its diverse range of medical and pharmaceutical products. The company's key revenue streams include ophthalmic products used in eye surgeries, medical aesthetics products for cosmetic procedures, and orthopedic products for bone and joint health. Additionally, it offers anti-adhesion and hemostatic solutions used in surgical procedures. The company also benefits from strategic partnerships and collaborations with healthcare providers, research institutions, and distributors, which enhance its market presence and distribution capabilities. These partnerships, along with a strong emphasis on research and development, contribute significantly to its earnings by driving product innovation and expanding its market reach.

Shanghai Haohai Biological Technology Co., Ltd. Class H Financial Statement Overview

Summary
Shanghai Haohai Biological Technology Co., Ltd. demonstrates strong revenue growth and profitability, supported by a robust balance sheet with low leverage. However, missing data in 2024 for key metrics could pose future analytical challenges. The company should focus on maintaining operational efficiency and improving cash flow visibility.
Income Statement
82
Very Positive
The company's revenue has shown consistent growth, with a notable increase from 2022 to 2023. The gross profit margin remains strong, indicating efficient cost management. Net income has also increased, demonstrating profitability. However, there is a slight decline in EBITDA margin, which could indicate rising operational costs.
Balance Sheet
78
Positive
The company has a strong equity position, with liabilities being significantly lower than stockholders' equity, leading to a healthy debt-to-equity ratio. However, the absence of total assets in 2024 data makes it challenging to calculate key ratios like equity ratio and return on equity (ROE) for the latest year.
Cash Flow
70
Positive
Operating cash flow showed substantial growth in 2023 but is missing for 2024, which raises concerns about cash management. The free cash flow turned positive in 2023, showing improved cash efficiency. However, the lack of data for 2024 limits further analysis.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.67B2.68B2.63B2.10B1.75B1.32B
Gross Profit1.47B1.87B1.85B1.45B1.26B990.42M
EBITDA643.57M665.04M713.41M447.55M550.45M394.80M
Net Income412.92M420.45M416.12M180.47M352.23M230.07M
Balance Sheet
Total Assets7.13B7.12B7.11B6.89B6.95B6.30B
Cash, Cash Equivalents and Short-Term Investments2.66B2.76B2.75B2.54B2.91B3.11B
Total Debt452.51M448.43M407.95M118.26M105.51M108.08M
Total Liabilities1.18B1.20B1.09B990.02M890.07M564.46M
Stockholders Equity5.67B5.58B5.65B5.51B5.71B5.49B
Cash Flow
Free Cash Flow254.80M283.08M367.22M-85.85M70.19M66.21M
Operating Cash Flow440.55M648.57M634.45M231.30M342.29M262.07M
Investing Cash Flow-183.48M282.28M-376.65M-681.82M-148.09M316.92M
Financing Cash Flow-511.56M-390.35M-257.73M-288.35M-231.25M-190.06M

Shanghai Haohai Biological Technology Co., Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Negative
Last Price27.38
Price Trends
50DMA
28.18
Negative
100DMA
26.50
Positive
200DMA
25.80
Positive
Market Momentum
MACD
-0.16
Positive
RSI
42.52
Neutral
STOCH
17.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6826, the sentiment is Negative. The current price of 27.38 is below the 20-day moving average (MA) of 27.52, below the 50-day MA of 28.18, and above the 200-day MA of 25.80, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 42.52 is Neutral, neither overbought nor oversold. The STOCH value of 17.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6826.

Shanghai Haohai Biological Technology Co., Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
HK$12.15B14.486.98%3.99%-5.62%-9.71%
66
Neutral
10.87B76.054.02%48.38%0.00%
57
Neutral
13.49B-64.48-58.53%240.05%-140.09%
55
Neutral
20.69B-72.04-20.82%964.40%65.90%
53
Neutral
11.68B-20.400.00%1219.19%25.15%
46
Neutral
11.49B-40.39-15.31%-76.58%-4.90%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H
27.38
-2.03
-6.90%
HK:1672
Ascletis Pharma, Inc.
11.70
10.70
1070.00%
HK:2157
Lepu Biopharma Co. Ltd. Class H
7.26
4.31
146.10%
HK:2162
Keymed Biosciences, Inc.
73.70
38.30
108.19%
HK:2171
CARsgen Therapeutics Holdings Ltd.
20.28
17.13
543.81%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
27.40
21.29
348.45%

Shanghai Haohai Biological Technology Co., Ltd. Class H Corporate Events

Shanghai Haohai Biological Announces Interim Dividend for 2025
Aug 22, 2025

Shanghai Haohai Biological Technology Co., Ltd. has announced an interim cash dividend of RMB 0.4 per share for the six-month period ending June 30, 2025. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.096155, with a payment date set for October 17, 2025. The announcement reflects the company’s financial health and commitment to returning value to its shareholders. The dividend distribution also involves withholding tax implications for both resident and non-resident shareholders, with varying rates based on residency and applicable tax treaties.

The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.

Shanghai Haohai Reports Decline in Revenue and Profit for H1 2025
Aug 22, 2025

Shanghai Haohai Biological Technology Co., Ltd. reported a decrease in revenue and profit for the six-month period ending June 30, 2025, compared to the same period in 2024. Revenue fell by approximately 7.48% to RMB1,292.64 million, while profit attributable to ordinary equity holders decreased by 10.29% to RMB211.07 million. Despite these declines, the company maintained its interim dividend at RMB0.40 per share. The decrease in R&D expenses by 21.53% and a slight improvement in other income and gains were notable financial movements during the period.

The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.

Shanghai Haohai Announces 2025 Interim Dividend Distribution
Aug 22, 2025

Shanghai Haohai Biological Technology Co., Ltd. has announced the distribution and payment of an interim dividend for 2025, amounting to RMB0.40 per share, totaling RMB91,493,200.00. The dividend will be distributed to H Shareholders in Hong Kong Dollars, with payments scheduled for October 17, 2025. The company has also outlined tax arrangements for non-resident enterprise shareholders and individual holders of H shares, ensuring compliance with the Enterprise Income Tax Law of the People’s Republic of China.

The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.

Shanghai Haohai Biological Technology Schedules Board Meeting for Interim Results
Aug 12, 2025

Shanghai Haohai Biological Technology Co., Ltd. has announced that its board of directors will meet on August 22, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the possibility of declaring an interim dividend, which could impact shareholder returns and reflect the company’s financial health.

Shanghai Haohai Adjusts A Shares Repurchase Price Cap
Jun 30, 2025

Shanghai Haohai Biological Technology Co., Ltd. announced an adjustment to the share price cap for its A shares repurchase plan. The company has reduced the maximum repurchase price to RMB88.72 per share following the approval of its 2024 profit distribution plan and the completion of the final dividend distribution. This adjustment is part of the company’s ongoing strategy to manage its share capital effectively, adhering to relevant regulations and market conditions.

Shanghai Haohai Biological Technology Announces Board Composition
Jun 10, 2025

Shanghai Haohai Biological Technology Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board consists of executive, non-executive, and independent non-executive directors, with various members serving on four key committees: Audit, Remuneration and Review, Nomination, and Strategy and Sustainable Development. This announcement underscores the company’s commitment to structured governance and strategic oversight, potentially impacting its operational efficiency and stakeholder confidence.

Shanghai Haohai Enhances Governance with New Audit Committee
Jun 10, 2025

Shanghai Haohai Biological Technology Co., Ltd. has established an audit committee to enhance its corporate governance and financial oversight. The committee is responsible for reviewing financial information, supervising audits, and ensuring effective management oversight, which is expected to strengthen the company’s decision-making and governance structure.

Shanghai Haohai Biological Technology Enhances Governance with New Remuneration Committee
Jun 10, 2025

Shanghai Haohai Biological Technology Co., Ltd. has established a remuneration and appraisal committee under its Board of Directors to enhance its remuneration management system. This committee is responsible for setting performance evaluation indicators and remuneration systems for directors and senior management, ensuring a formal and transparent process for developing remuneration policies, and making recommendations on remuneration packages. The move aims to align the company’s governance with regulatory requirements and improve oversight of executive compensation, potentially impacting its market positioning and stakeholder confidence.

Shanghai Haohai Enhances Governance with New Nomination Committee
Jun 10, 2025

Shanghai Haohai Biological Technology Co., Ltd. has established a Nomination Committee under its Board of Directors to enhance corporate governance. This committee is responsible for setting criteria and procedures for selecting directors and senior management, ensuring the board’s composition aligns with the company’s strategic goals, and maintaining board diversity. This move aims to optimize board operations and improve decision-making processes, which could strengthen the company’s industry positioning and stakeholder confidence.

Shanghai Haohai Biological Technology Approves Key Resolutions at Annual Meetings
Jun 10, 2025

Shanghai Haohai Biological Technology Co., Ltd. successfully held its Annual General Meeting and class meetings for A and H shareholders, where all proposed resolutions were approved. Significant decisions included the 2024 profit distribution, election of a new board session, and the abolishment of the supervisory committee, which are expected to impact the company’s governance and operational strategies.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 20, 2025